Metabolic syndrome and breast cancer risk
- PMID: 38123741
- DOI: 10.1186/s43046-023-00203-1
Metabolic syndrome and breast cancer risk
Abstract
Background: Limited data are available on metabolic syndrome and its relation to breast cancer risk in Egypt. We aimed to study metabolic syndrome and its individual components as risk of breast cancer.
Methods: This case-control study recruited 112 breast cancer cases and 112 age-matched controls from Assiut University. In addition to demographic, clinical, and anthropoemetric characteristics, blood samples were collected from both study groups to evaluate metabolic syndrome and its individual components.
Results: Mean age of breast cancer cases and control groups was 46.10 ± 4.34 and 45.66 ± 4.68 years, respectively. According to Joint Interim Statement (JIS) criteria for clinical diagnosis of metabolic syndrome, the overall prevalence of metabolic syndrome in all participants was 42.9%, and prevalence in breast cancer cases and control group was 57.14% and 28.6%, respectively, OR 33.33, 95% CI (1.91-5.81). BMI was more likely to be higher in breast cancer patients with a linear trend, p < 0.001. For individual components of metabolic syndrome, breast cancer cases were more likely to have high fasting blood glucose level, systolic and/or diastolic blood pressure, high triglycerides level, and low HDL-C as compared to the control group.
Conclusion: Metabolic syndrome and its components were found to be associated with the risk of breast cancer. We believe that prevention or reversal of metabolic syndrome by raising community awareness for lifestyle changes could be an effective way in minimizing the toll of the disease.
Keywords: Breast cancer; Case–control; Metabolic syndrome.
© 2023. The Author(s).
References
-
- GLOBOCAN. GLOBOCAN 2020: New Global Cancer Data. Website. 2020.
-
- Wu YT, Luo QQ, Li X, Arshad B, Xu Z, Ran L, et al. Clinical study on the prevalence and comparative analysis of metabolic syndrome and its components among Chinese breast cancer women and control population. J Cancer. 2018;9(3).
-
- Bansal R, Gubbi S, Muniyappa R. Metabolic syndrome and COVID 19: endocrine-immune-vascular interactions shapes clinical course. Endocrinology (United States). 2020;161.
-
- Lee DY, Lee TS. Associations between metabolic syndrome and gynecologic cancer. Obstet Gynecol Sci. 2020;63(3).
-
- Rigamonti AE, Cicolini S, Tamini S, Caroli D, Cella SG, Sartorio A. The age-dependent increase of metabolic syndrome requires more extensive and aggressive non-pharmacological and pharmacological interventions: a cross-sectional study in an Italian Cohort of Obese Women. Int J Endocrinol. 2021;2021.
MeSH terms
Substances
LinkOut - more resources
Medical